Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo bests single therapy in metastatic RCC

Motzer RJ et al. GU Cancers Symposium Abstract 578

Key clinical point: The combination of atezolizumab and bevacizumab is more efficacious than single-agent sunitinib as first-line therapy for metastatic RCC.

Major finding: Among patients with PD-L1-positive disease, median investigator-assessed progression-free survival was 11.2 months with atezolizumab-bevacizumab and 7.7 months with sunitinib (hazard ratio, 0.74; P = .02).

Data source: A randomized phase 3 trial among 915 patients with treatment-naive advanced or metastatic RCC (IMmotion151 trial).

Disclosures: Dr. Motzer disclosed that he has a consulting or advisory role with Pfizer, Novartis, Eisai, Exelixis, and Merck, and that his institution receives research funding from Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Eisai, Novartis, and Genentech/Roche. The study was sponsored by Genentech/Roche.

Source: Motzer RJ et al. GU Cancers Symposium Abstract 578


Motzer RJ et al. GU Cancers Symposium Abstract 578

This Week's Must Reads

How do you pronounce that drug name?, Frank D. JAMA Intern Med. 2018;178(3):319-320. doi:10.1001/jamainternmed.2017.7898

'Glass ceiling' extends to biomedical industry payments, Tringale K and Hattangadi-Gluth J. JAMA Intern Med. 2018;178(3):421-423. doi:10.1001/jamainternmed.2017.7445

Mining social media to detect adverse drug reactions to newly-approved drugs, Ransohoff J et al. JAMA Oncology March 1, 2018. doi:10.1001/jamaoncol.2017.5688

Insurance type linked to cancer care delays, Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.

Intervention boosted the rate of colorectal cancer screening, Source: Miller, D et al. Ann Inter Med 2018. DOI: 10.7326/M17-2315

Must Reads in Renal Cell Carcinoma

Six factors predict urothelial cancer response, Pond GR et al. GU Cancers Symposium Abstract 413

Combo bests single therapy in metastatic RCC, Motzer RJ et al. GU Cancers Symposium Abstract 578

Chemo is best course in resected urothelial disease, Birtle A et al. Genitourinary Cancers Symposium. Abstract 407.

Selecting chemoradiation in bladder cancer, Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.

When to choose surgery or surveillance in RCC, Hakimi A et al. J Urol. 2018 Feb 26 doi: 10.1016/j.juro.2018.02.3087.